Skip to main content

Table 4 Comparison between pre-treatment and post-treatment lipid profile and Lp-PLA2 in patients who failed to achieve SVR (n = 4)

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Lipid parameter Time Paired t-test
Pre-treatment 12 weeks post-treatment t p
LDL (mg/dl) 33.75 ± 4.573 (27–37) 36.5 ± 4.655 (30–41) −2.200 0.115
Total cholesterol (mg/dl) 114 ± 32.527 (87–158) 117.5 ± 28.361 (88–153) −1.000 0.391
HDL (mg/dl) 38.75 ± 6.702 (32–48) 37.25 ± 5.123 (30–42) 0.878 0.444
Lp-PLA2 (ng/ml) 370 ± 98.668 (260–474) 392.25 ± 88.733 (319–500) −1.648 0.198
  1. Abbreviations: n, number; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2